SunOpta Q3 revenue up 5.9% to $152.5M; loss from continuing ops of $5.7M vs prior year profit

SunOpta Inc.

2023-Q3 EPS reported -$1.45 revenue$448,673,000

Revenue $152.5M, up 5.9% YoY on 5.5% volume growth; adjusted EBITDA $19.1M, up 8.1% from $17.7M.
Loss from continuing ops $5.7M vs earnings $2.4M in Q3 2022; diluted EPS loss $0.05 vs +$0.01.
Divested frozen fruit on Oct 12 for ~$141M; recorded pre-tax loss of $118.8M in discontinued ops ($140.1M total).
Net debt reduced: used $74.8M of proceeds to repay revolver; plans to replace ABL with term loan/revolver by year-end.
FY2024 outlook: revenue $670-700M (+8-13%) and adjusted EBITDA $87-92M (+14-21%), both driven by volume.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SunOpta Inc. reported third quarter ended September 30, 2023 results: revenue $152.5 million, net income $5.7 million, EPS $0.05 per diluted share. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: $152.5 million
Net income: $5.7 million
EPS: $0.05 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

- Filed by newsfilecorp.com Exhibit 99.1 FOR IMMEDIATE RELEASE SUNOPTA ANNOUNCES THIRD QUARTER FISCAL 2023 FINANCIAL RESULTS Revenue from continuing operations increased 5.9% to $152.5 million, driven by 5.5% volume growth Loss from continuing operations of $5.7 million, compared to earnings of $2.4 million in the prior year Adjusted EBTIDA from continuing operations

View on SEC.gov

Browse all earnings releases →

SunOpta Inc. filing history →

Source: SEC EDGAR

accession 0001062993-23-020338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.